-
Bristol-Myers Squibb Q2 2023 Results Miss Estimates, Full-Year Guidance Revised Downward
•
US pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has released its financial report for the second quarter of 2023, which showed performance below expectations and led to a downward revision in full-year guidance. Revenues for the quarter decreased by 5% year-on-year (YOY) in constant exchange rate terms to USD 11.2…
-
Pfizer Announces Leadership Shake-Up with Focus on Oncology R&D
•
Pfizer Inc., (NYSE: PFE) has announced significant changes in its Research and Development (R&D) leadership. Dr. Chris Boshoff has been promoted to the role of Chief Oncology R&D Officer and Executive Vice-President (EVP), marking an internal shift as he previously managed clinical research for Pfizer’s oncology and rare disease portfolio.…
-
Roche Group’s H1 2023 Financial Report: Pharmaceuticals Grow While Diagnostics Dip
•
Swiss pharmaceutical giant Roche Group (SWX: ROG) has released its half-yearly financial report for 2023, showing a -2% year-on-year (YOY) decline in group sales to CHF 29.8 billion (USD 34.5 billion) in constant exchange rate terms. Within the group, Pharmaceuticals saw an 8% YOY increase to CHF 22.7 billion (USD…
-
MSD’s V116 Vaccine Shows Superior Immune Response in Phase III Trials
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed positive topline results from two Phase III trials assessing the company’s 21-valent pneumococcal conjugate vaccine candidate, V116. This vaccine, the first of its kind designed for use in adults, is being evaluated in a comprehensive clinical trial program involving 2,600 patients.…
-
Pharmaniaga Berhad and CSPC Pharmaceutical Group Broaden Collaboration in Pharma and Biopharma
•
Malaysia-based pharmaceutical company Pharmaniaga Berhad has announced the signing of a comprehensive collaboration with China’s CSPC Pharmaceutical Group Ltd (HKG: 1093). The agreement, formalized through a memorandum of understanding (MoU) between their respective subsidiaries, Pharmaniaga LifeScience Sdn Bhd and CSPC Ouyi Pharmaceutical Co., Ltd, encompasses research and development (R&D), manufacturing,…
-
Thermo Fisher Scientific Reports Q2 2023 Revenue Dip, Adjusts Full-Year Forecast
•
US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has released its financial results for the second quarter of 2023, showing a 3% year-on-year (YOY) decrease in revenues in constant currency terms, amounting to USD 10.69 billion. CEO Marc Casper attributed the decline to a more challenging macroeconomic environment,…
-
AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research
•
AbbVie (NYSE: ABBV) and US-based Calibr, the nonprofit drug discovery division of San Diego research institute Scripps Research, have unveiled a strategic collaboration aimed at advancing preclinical research. This partnership builds on previous work with Scripps that has already led to the development of several preclinical and early clinical drug…
-
GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance
•
UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the second quarter of 2023, demonstrating a robust performance with sales revenues increasing by 4% year-on-year (YOY) in constant currency terms to GBP 7.178 billion (USD 9.3 billion). Excluding COVID-19-related sales, the growth was even more…
